a buffer may suitably be prepared at ph ranging from 5 . 0 to 10 . 0 . at ph more acidic than this range , stability of fviia and / or fx in the solution will be impaired wherein fviia and / or fx are gradually inactivated . at ph more basic than this range , stability of fviia and / or fx in the solution is also not sufficient and hence the proteins are inactivated gradually . at ph 6 . 5 to 10 . 0 , however , the substrate fx is converted into fxa by fviia . therefore , ph ranging from 5 . 0 to 6 . 5 , preferably from 5 . 4 to 6 . 1 , may be used , by which there is no concern about impairment of the activity of each component or conversion from fx into exa . fviia and fx for use in the present invention may be prepared by any known methods , for example , by isolating from human blood or by the genetic recombination technique . fviia may be prepared from blood by the known methods including those disclosed in e . g . japanese patent publication no . 155797 / 1991 , japanese patent publication no . 059866 / 1998 and japanese patent - publication no . 059867 / 1998 . alternatively , fviia may be prepared by applying cryo - poor plasma , which is prepared by cool - thawing human fresh frozen plasma and removing cryoprecipitate by centrifugation , to anion exchange chromatography to give crude fvii , which is then purified by affinity column chromatography with immobilized anti - fvii monoclonal antibody , followed by activation of fvii with other plasma proteins such as activated blood coagulation factor xii , or exa . to ensure safety , the resulting fviia may preferably be contaminated with as little prothrombin , thrombin , fix and fixa as possible . fx may be prepared from blood by applying cryo - poor plasma , which is prepared by cool - thawing human fresh frozen plasma and removing cryoprecipitate by centrifugation , to anion exchange chromatography to give crude fx , which is then purified by affinity column chromatography with immobilized anti - fx monoclonal antibody . like in case of fviia , to ensure safety , the resulting fx may preferably be contaminated with as little prothrombin , thrombin , fix and fixa as possible . the liquid composition of the present invention may suitably comprise fviia at 1 to 20 μm and fx at 5 to 400 μm . in a preferable embodiment , the liquid composition of the present invention may additionally comprise 0 . 001 to 1 % by weight non - ionic surfactant , and not less than 0 . 01 % by weight of one or more compounds selected from the group consisting of albumin , sugars and amino acids , to thereby allow for storage stability of the composition as well as to facilitate dissolution at reconstitution in case that said liquid composition is lyophilized . the composition or the hemostatic preparation of the present invention may be administered to any patients who suffer from various hemostatic disorders and demonstrate hemorrhagic inclination . the present invention provides a novel hemostatic preparation with improved safety , efficacy and facility . the present invention is explained in more detail by means of the following examples which are not intended to restrict the scope of the present invention in any sense . in order to investigate stability of a fviia / fx mixture in a buffer solution , 0 . 4 mg / ml fviia and 1 . 0 mg / ml fx were mixed together in a buffer solution ( mes buffer in the absence of cacl 2 : 100 mm mes , 100 mm nacl ) at specified ph and the mixture was incubated at 37 ° c . the activity of each fviia , fx and fxa in a sample was measured at each specified time in a system where any of these factors does not affect to each other . fviia used herein was a blood - derived product prepared as described in japanese patent publication no . 155797 / 1991 . as a result , both fviia and fx retained more than 90 % activity after incubation for 24 hours at every ph values of the buffer tested . a content of fxa was calculated on the basis of its specific hydrolytic activity to a synthetic substrate ( s2222 ) and a molar ratio of the content to fx is shown in fig2 . no increase in a content of fxa was observed in the buffer at ph 5 . 6 and 6 . 0 while drastic increase in a content of fxa was detected in the buffer at ph 7 . 0 and 8 . 0 . in order to investigate stability of a fviia / fx mixture in a buffer solution after lyophilization , 0 . 4 mg / ml fviia and 1 . 0 mg / ml fx were mixed together in a buffer solution [ citrate buffer in the absence of cacl 2 : 10 mm sodium citrate , 120 mm nacl , 0 . 5 % glycine , 2 % albumin , and 50 ppm tween ® 80 ( polysorbate 80 )] at specified ph to prepare a bulk , which was lyophilized . as in example 1 , fviia used herein was a blood - derived product prepared as described in japanese patent publication no . 155797 / 1991 . the activity of each factor was measured before and after lyophilization as described in example 1 and the content of fxa is shown in fig3 . as a result , both fviia and fx retained more than 80 % activity before and after lyophilization at every ph value of the buffer tested . no increase in a content of fxa was observed in the buffer at ph 5 . 5 and 6 . 0 while drastic increase in a content of fxa was detected in the buffer at ph 7 . 0 .
a novel hemostatic composition and a hemostatic pharmaceutical preparation are provided . a pharmaceutically stable hemostatic liquid composition comprising a mixed solution of activated blood coagulation factor vii and blood coagulation factor x in a single container . the mixed solution is maintained at ph ranging from 5 . 0 to 6 . 5 .